HomeNewsms, msbiomarker, multiple sclerosis, nflNovel Multiple Sclerosis Biomarker to measure severity of disease, suggests study

Novel Multiple Sclerosis Biomarker to measure severity of disease, suggests study

  • April 20, 2018
  • Posted by: PharmaScroll
  • Category:
No Comments

m-the-severity-of-multiple-sclerosis-diagnostics-on-the-retina

A recent study, which would be presented in AAN 2018, suggested and supported the value of sNfL as a biomarker for disease severity and treatment monitoring in MS patients. The study was conducted with an aim to evaluate serum neurofilament light (sNfL) as a prognostic and disease/treatment monitoring biomarker in multiple sclerosis (MS) patients utilizing a large well-characterized cohort of MS patients from Biogen Phase III clinical trials.

During the study, sNfL levels were measured using a sensitive Single Molecule Array (SIMOA, Quanterix) assay in serial samples from >750 patients enrolled in three Phase III trials: CHAMPS (IFNβ1a in clinically isolated syndrome, CIS, n=319), ADVANCE (PEGylated-IFNβ1a in relapsing-remitting MS, RRMS, n=310), and SENTINEL (natalizumab in RRMS, n=122). Statistical analyses to evaluate associations between sNfL and key clinical and MRI parameters included Spearman correlation, ANOVA, chi-squared test, Kaplan-Meier analysis and multivariate logistic regression.

Results of the study:

sNfL levels were associated concurrently with number of enhancing lesions (p<0.00001) and T2 lesion volume (p<0.00001), as well as long-term with various clinical and paraclinical outcome measures, including EDSS progression (up to 5 years, p<0.05), T2 lesion volume and new T2 lesions (up to 10 years, p<0.00001), and brain atrophy (5 years p<0.00001). In patients with no evident disease activity, sNfL levels remained consistently low and stable (mean 8.4 pg/mL; mean within-patient coefficient of variation, CV=22%). In contrast, in patients with active disease, sNfL levels were elevated (mean 25 pg/mL) and more variable (CV=31%). Finally, sNfL levels were lowered in the experimental treatment arms, with the most pronounced effects observed for natalizumab. Detailed analyses describing effects of the treatments on sNfL will be presented.

The study concluded that the findings support the value of sNfL as a biomarker for disease severity and treatment monitoring in MS patients.

The detailed results of the study would be presented and discussed at the annual meeting of the American Academy of Neurology in Los Angeles, April 21-27.

 

About Pharmascroll:

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

To read more news about Multiple Sclerosis, visit https://pharmascroll.com/news-category/multiple-sclerosis/

 

News Source: http://n.neurology.org/content/90/15_Supplement/S24.003

Image Source: http://diagnoz.artdevue.com/en/news/the-severity-of-multiple-sclerosis-diagnostics-on-the-retina.html